华润三九 (000999)
China Resources Sanjiu Medical & Pharmaceutical Co., Ltd.
K-Line Chart
No K-line data
Stock Details
1. Key Indicators
- Total Shares(W): 166421.79
- Circulating A-Shares(W): 166269.40
- Earnings Per Share(RMB): 1.4200
- Net Assets Per Share(RMB): 12.6878
- Operating Revenue(W RMB): 2198640.40
- Total Profit(W RMB): 343060.99
- Net Profit Attributable to Parent(W RMB): 235282.70
- Net Profit Growth Rate(%): -20.51
- Weighted Return on Equity(%): 11.4700
- Operating Cash Flow Per Share(RMB): 1.7580
- Undistributed Profit Per Share(RMB): 10.3685
- Capital Reserve Per Share(RMB): 0.8448
2. Main Business
The main business covers:
- Development, production, and sales of pharmaceuticals
- Cultivation of Chinese medicinal herbs
- Development, transfer, and services of related technologies
- Import business of machinery, equipment, and raw materials required for production
- Export of self-produced products
- Wholesale of prepackaged food (excluding reheating)
- Development and sales of cosmetics and Class I medical devices
- Leasing of self-owned properties and motor vehicle parking services
3. Company Basic Information
- Company Name: China Resources Sanjiu Medical and Pharmaceutical Co., Ltd.
- Listing Date: 2000-03-09
- Industry: Pharmaceutical Manufacturing
- Address: No. 1 Guanqing Road, Guanlan High-tech Park, Guanhu Street, Longhua District, Shenzhen City, Guangdong Province
- Website: www.999.com.cn
- Company Profile: The company was established as a joint-stock company, with Shenzhen Sanjiu Pharmaceutical Co., Ltd. as the main sponsor, jointly initiated with Sanjiu Enterprise Group, Shenzhen Jiu Xian Bioengineering Co., Ltd., Shenzhen Xiandaming Trading Co., Ltd., and Huizhou Renxing Industrial and Trade Co., Ltd. Shenzhen Sanjiu Pharmaceutical Co., Ltd. and Sanjiu Enterprise Group contributed net assets and cash, converted into 552 million state-owned legal person shares. The other three sponsors contributed cash, totaling 1 million shares. The company's total share capital was 553 million shares. After the public issuance of 200 million ordinary shares from November 11 to 12, 1999, the company's total share capital reached 753 million shares.
4. Top 10 Circulating Shareholders
| Rank | Institution Name | Institution Type | Shares Held (W) | Percentage Held (%) |
|---|---|---|---|---|
| 1 | China Resources Pharmaceutical Holding Co., Ltd. | General Legal Person | 105214.27 | 63.28 |
| 2 | China Chengtong Holdings Group Co., Ltd. | Special Legal Person | 3387.22 | 2.04 |
| 3 | Hong Kong Securities Clearing Company Ltd. | Northbound Capital | 3378.11 | 2.03 |
| 4 | Huatai-PineBridge CSI 300 ETF | Fund | 1145.40 | 0.69 |
| 5 | E Fund Yu Xiang Return Bond Securities Investment Fund Class A | Fund | 846.16 | 0.51 |
| 6 | E Fund CSI 300 Healthcare ETF | Fund | 837.33 | 0.50 |
| 7 | E Fund CSI 300 ETF | Fund | 821.87 | 0.49 |
| 8 | TEMASEK FULLERTON ALPHA PTE LTD | QFII | 793.03 | 0.48 |
| 9 | Guoxin Investment Co., Ltd. | Special Legal Person | 647.28 | 0.39 |
| 10 | ChinaAMC CSI 300 ETF | Fund | 613.34 | 0.37 |
5. Concept Sectors
- Photovoltaic
- Generic Drugs
- Mask Protection
- Green Power
- Innovative Drugs
- Margin Trading & Securities Lending
- High-Performance Stocks
- QFII Heavy Holdings
- Restructuring Stocks
- Northbound Heavy Holdings
- Mainland-HK Stock Connect Heavy Holdings
- Non-Cyclical Stocks
- Central Enterprises 100
- SZSE Value
- Mid-Cap Growth
- Mid-Cap Value
- SZSE 100
- SZSE 300
- SZSE Dividend
- SZSE Growth
- SZSE Growth
- CSI 300
- CSI 200
- CSI 300 Non-Cyclical
- CSI Central Enterprises
- CSI 300 ESG
- Emerging Composite Index
- Pearl River Delta
- SZSE Main Board 50
Remarks
- Data update date: 2026-01-01
- Data source: Public Market Information